Maximum quantity allowed is 999
Please select the quantity
CAS RN: 179688-29-0 | Product Number: B4270
6,7-Bis(2-methoxyethoxy)-3H-quinazolin-4-one
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone
- 6,7-Bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one
- 6,7-Bis(2-methoxyethoxy)-4-hydroxyquinazoline
- 6,7-Bis(2-methoxyethoxy)-4-quinazolinol
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
₩56,600
|
0 | 2 | It can be shipped in about 3-4 weeks after ordering | |
| 5G |
₩212,600
|
1 | 2 | It can be shipped in about 3-4 weeks after ordering |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | B4270 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__4H__1__8N__2O__5 = 294.31 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| CAS RN | 179688-29-0 |
| Reaxys Registry Number | 10087641 |
| PubChem Substance ID | 253660263 |
| MDL Number | MFCD02678087 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 190.0 to 194.0 °C |
Properties (reference)
| Melting Point | 192 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2933.59-000 |
Application
A Key Synthetic Intermediate of Erlotinib
This product is a key synthetic intermediate of erlotinib which is a receptor tyrosine kinase inhibitor acting on the epidermal growth factor receptor (EGFR), such as gefitinib [G0546].
References
- Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib
- Improved Synthesis of Gefitinib and Erlotinib Hydrochloride-Anticancer Agents
- Modified Synthesis of Erlotinib Hydrochloride
- Separation and determination of process-related impurities of erlotinib using reverse-phase HPLC with a photo-diode array detector
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.